Subscribe to stay informed!
A Malvern-based biotech company is making an advantageous acquisition. Baudax Bio will be inheriting an abundance of products following its transaction with Maryland-based…
Malvern-based pharmaceutical company Baudax Bio has completed $5 million in stock sales, writes John George for the Philadelphia Business Journal. The proceeds made from…
Malvern-based Baudax Bio is selling a little over 11.8 million shares of its common stock in a public stock offering that is expected…
Malvern-based Baudax Bio has signed a loan deal with Marathon Asset Management worth $50 million to support the launch of its intravenous and non…
Baudax Bio launched its new, non-opioid pain medication earlier this week, but due to the ongoing coronavirus crisis, the Malvern-based company is relying…
Before we send you to this site, please subscribe to our daily newsletter.